# Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese

Source: https://onco.cc/trials/nct06107413/  
OnCo record `nct06107413` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telisotuzumab adizutecan, Bevacizumab, Leucovorin in colorectal cancer, run by AbbVie, active and no longer recruiting.

## Summary

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab is a phase 2 interventional study registered as NCT06107413 by AbbVie, with 280 participants planned, started 2023-11-12 and due to reach its primary completion in 2026-12. Interventions recorded: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan. Conditions listed: Unresectable Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06107413
- Phase: 2
- Setting: A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer
- Sponsor: AbbVie
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06107413: https://clinicaltrials.gov/study/NCT06107413

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06107413.json